Are the Antagonists of the Renin–Angiotensin System Also Anticancer Agents?
- First Online:
- Cite this article as:
- Lonati, C. & Morganti, A. High Blood Press Cardiovasc Prev (2015) 22: 99. doi:10.1007/s40292-014-0059-y
- 76 Views
The antagonists of the renin–angiotensin system (RAS) have gained increasing popularity in the last two decades due to their indisputable efficacy in a number of cardiovascular disorders, coupled with an unsurpassed tolerability. However some years ago a partial and non-predefined meta-analysis raised the possibility that angiotensin receptor antagonists in particular may increase the incidence of cancer. This observation, although not confirmed by subsequent, larger analyses, caused a remarkable and understandable concern even outside the medical community. Herein we will summarize the available evidence pro and con the hypothesis of a carcinogenetic activity of RAS antagonists coming to the conclusion that these drugs may actually exert an anticancer action.